US20090299253A1 - Blood clotting compositions and wound dressings - Google Patents
Blood clotting compositions and wound dressings Download PDFInfo
- Publication number
- US20090299253A1 US20090299253A1 US12/510,203 US51020309A US2009299253A1 US 20090299253 A1 US20090299253 A1 US 20090299253A1 US 51020309 A US51020309 A US 51020309A US 2009299253 A1 US2009299253 A1 US 2009299253A1
- Authority
- US
- United States
- Prior art keywords
- blood
- zeolite
- wound
- clay material
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000023555 blood coagulation Effects 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title description 30
- 239000000463 material Substances 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 30
- 239000004927 clay Substances 0.000 claims abstract description 18
- 230000000740 bleeding effect Effects 0.000 claims description 19
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000005995 Aluminium silicate Substances 0.000 claims description 5
- 235000012211 aluminium silicate Nutrition 0.000 claims description 5
- 229910000278 bentonite Inorganic materials 0.000 claims description 5
- 239000000440 bentonite Substances 0.000 claims description 5
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 5
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 5
- 229910052622 kaolinite Inorganic materials 0.000 claims description 5
- 229910052901 montmorillonite Inorganic materials 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 239000010457 zeolite Substances 0.000 abstract description 54
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 abstract description 48
- 229910021536 Zeolite Inorganic materials 0.000 abstract description 46
- 210000004369 blood Anatomy 0.000 abstract description 39
- 239000008280 blood Substances 0.000 abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 239000002808 molecular sieve Substances 0.000 abstract description 20
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 abstract description 20
- 230000008569 process Effects 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 229910052809 inorganic oxide Inorganic materials 0.000 abstract description 4
- 150000003384 small molecules Chemical class 0.000 abstract description 3
- -1 water Chemical class 0.000 abstract description 3
- 206010052428 Wound Diseases 0.000 description 48
- 208000027418 Wounds and injury Diseases 0.000 description 40
- 208000032843 Hemorrhage Diseases 0.000 description 16
- 238000006703 hydration reaction Methods 0.000 description 14
- 230000036571 hydration Effects 0.000 description 13
- 238000001035 drying Methods 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 206010053567 Coagulopathies Diseases 0.000 description 7
- 230000035602 clotting Effects 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 6
- 239000007791 liquid phase Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910000287 alkaline earth metal oxide Inorganic materials 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- UNYSKUBLZGJSLV-UHFFFAOYSA-L calcium;1,3,5,2,4,6$l^{2}-trioxadisilaluminane 2,4-dioxide;dihydroxide;hexahydrate Chemical compound O.O.O.O.O.O.[OH-].[OH-].[Ca+2].O=[Si]1O[Al]O[Si](=O)O1.O=[Si]1O[Al]O[Si](=O)O1 UNYSKUBLZGJSLV-UHFFFAOYSA-L 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910052676 chabazite Inorganic materials 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229910052677 heulandite Inorganic materials 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052674 natrolite Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 229910001404 rare earth metal oxide Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical group 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910052678 stilbite Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- the present invention relates to blood clotting devices (also referred to as hemostatic agents) and methods of controlling bleeding and, more particularly, to blood clotting materials and compositions for use as bleeding control devices.
- Blood is a liquid tissue that includes red cells, white cells, corpuscles, and platelets dispersed in a liquid phase.
- the liquid phase is plasma, which includes acids, lipids, solublized electrolytes, and proteins.
- the proteins are suspended in the liquid phase and can be separated out of the liquid phase by any of a variety of methods such as filtration, centrifugation, electrophoresis, and immunochemical techniques.
- One particular protein suspended in the liquid phase is fibrinogen. When bleeding occurs, the fibrinogen reacts with water and thrombin (an enzyme) to form fibrin, which is insoluble in blood and polymerizes to form clots.
- thrombin an enzyme
- animals can be wounded. Often bleeding is associated with such wounds. In some instances, the wound and the bleeding are minor, and normal blood clotting functions in addition to the application of simple first aid are all that is required. Unfortunately, however, in other circumstances, substantial bleeding can occur. These situations usually require specialized equipment and materials as well as personnel trained to administer appropriate aid. If such aid is not readily available, excessive blood loss can occur. When bleeding is severe, sometimes the immediate availability of equipment and trained personnel is still insufficient to stanch the flow of blood in a timely manner.
- compositions for promoting the formation of clots in blood have also been developed.
- Such compositions generally comprise zeolites and binders.
- the water content is estimated to be about 1.54% or less.
- the water content is estimated by measuring the mass of material before and after heating at 550 degrees C. (Loss on Ignition (LOI) at 550 degrees C.). Higher temperatures are sometimes used for LOI calculations, but procedures that utilize these higher temperatures increase the loss of chemical compounds other than water.
- LOI Liss on Ignition
- the basic material forming the wound dressing, covering, and/or application system of the present invention for use in blood coagulation comprises a combination of one or more components selected from the group consisting of clay materials, a molecular sieve material, principally zeolite, and inorganic oxide materials.
- the molecular sieve material selectively absorbs small molecules, such as water, from the blood. Due to the absorption of the water molecules, it is believed that the rate of blood clotting is increased.
- a composition for promoting the formation of clots in blood comprises a zeolite and a binder.
- the moisture content of the zeolite is adjusted by drying, re-hydrating, or a combination of drying and re-hydrating such that the zeolite has a specific moisture content.
- the composition may be fully saturated with water and subsequently dried to a specific water content.
- the bound water is removed to allow the crystalline structure of the zeolite to remain intact.
- the most active adsorption sites are hydrated first and then less active sites are hydrated.
- the heat of hydration decreases. More specifically, when the composition is applied to the blood, water in the blood is adsorbed by the zeolite. Upon adsorption of this water, heat is generated. At higher levels of hydration (hydration of the zeolite prior to its application to blood), less heat is generated when the composition is applied to blood. Thus, when the composition is applied to blood directly at a wound site, the amount of heat transferred to the tissue surrounding the wound site is reduced.
- a method of forming a blood-clotting composition comprises the steps of providing a zeolite in hydrated form and adjusting a moisture content of the zeolite to have a specific moisture content such that upon application of the composition to a wound, a heat of hydration is reduced and a heat transferred to the wound is reduced.
- a method of clotting blood flowing from a wound comprises the steps of applying a zeolite to the wound and maintaining the zeolite in contact with the wound for a predetermined amount of time, the zeolite having an adjusted moisture content and being capable of producing a controllable exothermic effect on the wound.
- One advantage of the present invention is that it is easily applied to an open wound. It can be readily removed from sterilized packaging and deposited directly at the points from which blood emanates to dress the wound.
- Another advantage of the present invention is that the rate of water adsorption is dramatically reduced as the degree of hydration increases from about 0.1% to about 4%. After about 4%, the rate of adsorption is slower. Also, after about 4%, the rate of adsorption changes more slowly.
- slower water adsorption is advantageous for two reasons. First, the humidity and temperature of the packaging environment has less of an affect, thereby allowing material to be exposed to the environment for a longer period of time without significantly changing the pre-hydration level. Second, the slower rate of water adsorption allows the heat of hydration to be dissipated over a longer period of time. Therefore, the composition is heated to a lower maximum temperature. Thus, less heat is transferred to the tissue of a wound without losing product efficacy (formation of clots in blood).
- the present invention is able to effectively clot traumatic bleeding of wounds better than other available methods for treating similar wounds.
- the material of the present invention was the only material proven to have a morbidity rate of 0% including a standard pressure dressing.
- the wound dressing, covering, and/or application system generally comprises, in its principal basic form, a unique composition or formulation which is easily applied to an open wound and rapidly and effectively promotes the clotting rate of any flowing blood. In this way, blood emanating from the open wound coagulates or clots in a rapid or accelerated manner.
- the wound dressing, coverings, and/or application system of the present invention comprises a molecular sieve material, which preferably consists of zeolite, in combination with a suitable binder in a sterilized form enabling its application directly to an open wound.
- a molecular sieve material which preferably consists of zeolite
- the wound treatment material may be applied directly to the open wound, as the sole component for inducing blood coagulation, it is preferable that the wound or opening is also treated with sterilized dressings, such as gauze, pads, multiple layer covers, films, permeable bandages, and the like. In this way, the rate of blood clotting is increased and the rate of blood loss from the wound is rapidly reduced.
- the basic material forming the wound dressing, covering, and/or application system of the present invention for use in blood coagulation comprises a combination of one or more components selected from the group consisting of clay materials, a molecular sieve material, principally zeolite, and inorganic oxide materials.
- the molecular sieve material selectively absorbs small molecules, such as water, from the blood. Due to the absorption of the water molecules, it is believed that the rate of blood clotting is increased.
- compositions of the present invention provide a highly effective blood coagulation product capable of being quickly and easily applied to any desired wound site for achieving rapid termination of blood flow.
- the present invention is capable of being employed in a wide variety of applications and/or uses.
- One principal use is in trauma situations, such as car accidents, where large open wounds may be produced with excessive blood loss.
- similar conditions are often found in military applications, particularly during armed conflicts.
- numerous other applications benefit from the use of the present invention, such as use in a surgical environment as well as in veterinary applications where animal bleeding occurs due to accidents or surgical operations.
- the molecular sieve material or zeolite forming a part of the composition of this invention is typically dehydrated in its final form, usually to a hydration level of about 0.5%.
- the application of the dehydrated zeolite material to the open wound produces an exothermic reaction, which often assists with the promotion of the coagulation of the blood.
- the exothermic reaction is substantial, causing damage to the surrounding tissue.
- the efficacy provided by the molecular sieve material/zeolite is enhanced by rehydrating the molecular sieve material/zeolite to a hydration level ranging between about 1% and 15%. In addition, it has been found that this hydration level more preferably ranges between about 2% and 8%.
- compositions and methods directed to the clotting of blood and the forming of blood clotting compositions generally include molecular sieves for minimizing or stopping bleeding by absorbing at least portions of the liquid phases of blood, thereby promoting clotting.
- the methods generally include the application of molecular sieves to bleeding wounds to provide dressings and removing components of the blood to facilitate the formation of clots.
- a molecular sieve comprises a zeolite and a binder.
- zeolite refers to a crystalline form of aluminosilicate that may include several ionic species including sodium and calcium moieties.
- the preferred molecular structure of the zeolite is referred to as an “A-type” crystal.
- A-type crystal is intended to indicate a crystal having a cubic crystalline structure and round holes.
- the zeolite may be ion-exchanged to include a specific cation, for example, calcium, sodium, potassium, silver, or magnesium, or any combination of the foregoing.
- Suitable zeolites for use in the applications disclosed herein are also preferably nanoporous so as to provide increased surface areas.
- nanoporous is intended to indicate an average pore diameter of about 3 angstroms to about 5 angstroms.
- the zeolite comprises irregularly-shaped granular material that is prepared by grinding larger particles and then selecting material that will pass through a 16 mesh sieve screen but will not pass through a 40 mesh sieve screen.
- the resulting zeolite is a composition of irregular granules that range in size from 0.4 millimeters (mm) in diameter to 0.8 mm in diameter.
- Zeolites for use in the disclosed applications may be naturally occurring or synthetically produced. Numerous varieties of naturally occurring zeolites are found as deposits in sedimentary environments as well as in other places. Naturally occurring zeolites that may be applicable to the compositions and methods described herein include, but are not limited to, analcite, chabazite, heulandite, natrolite, stilbite, and thomosonite. Synthetically produced zeolites that may also find use in the compositions and methods described herein are generally produced by processes in which rare earth oxides are substituted by silicates, alumina, or alumina in combination with alkali or alkaline earth metal oxides.
- the binder is preferably clay-based and may further include fillers (e.g., aluminum sulfate) or thickening agents that facilitate the selective application of the zeolite in various forms (e.g., as a paste, gel, powder, or erodible solid member).
- Fillers e.g., aluminum sulfate
- thickening agents that facilitate the selective application of the zeolite in various forms (e.g., as a paste, gel, powder, or erodible solid member).
- Natural clays that may provide suitable bases include, but are not limited to, kaolin, kaolinite, bentonite, montmorillonite, combinations of the foregoing clays, and the like. Modified clays such as polyorganosilcate graft polymers may also provide suitable bases.
- the moisture content of the zeolite is adjusted by drying, re-hydrating, or a combination of drying and re-hydrating the zeolite such that the zeolite has a specific moisture content.
- a fully hydrated zeolite has a moisture content of about 20 weight percent (wt. %). Drying of the zeolite may be effected by the application of heat. Upon heating, adsorbed water bound in the crystalline structure is driven off without altering the structure itself or detracting from its integrity. The dried zeolite may then be re-hydrated. Upon drying or drying and re-hydrating, the zeolite contains about 1.55 wt. % to about 10 wt.
- the drying process can be stopped before the material is completely dehydrated.
- the final hydration of the material can be controlled by monitoring and controlling the temperature of zones of a drying apparatus in which the material is dried.
- the hydrated zeolite material also generates less heat upon being fully-saturated with water in the application of the zeolite to the blood.
- the heat of hydration is inversely proportional to the moisture content. Therefore, a zeolite hydrated to a moisture content of 4 wt. % will generate measurably less heat than a zeolite that has been fully dehydrated to less than 0.1 wt. %. Both materials, however, will be fully-saturated with water upon application to a bleeding wound.
- the exothermic effects and heat transferred to the wound are reduced. Therefore, upon application of the composition of the present invention to a bleeding wound, less heat is transferred to the tissue of the wound.
- the remaining blood which includes cells, corpuscles, platelets, and plasma
- the platelets aggregate and interact with collagen, phospholipids, and lipid-containing proteins in the plasma.
- the aggregation of the platelets provide nuclei upon which fibrin binds to form a clot.
- Cells from the blood subsequently combine with the clot to form a mass.
- the formation of the mass from the clot causes the flow of blood to cease, thereby eliminating further loss of blood.
- the blood pressure will often noticeably increase upon application of the present invention due to cessation of blood loss.
- a molecular sieve containing partially re-hydrated zeolite was added to normal pooled plasma.
- the plasma was separated into two phases, namely, a heavy phase and a supernatant phase.
- the heavy phase included the typical blood plasma components as well as the reacted zeolite.
- the supernatant phase was tested to determine the levels of PT, aPTT, and fibrinogen, where “PT” is prothrombin time and “aPTT” is activated partial thromboplastin time.
- PT and aPPT are assays that provide time values that are compared to other samples or to a hemotological standard. The time values are used indirectly to suggest the levels of clotting factors present in pooled plasma.
- a control comprising serum was also tested to determine the levels of the same components.
- the PT, aPTT, and fibrinogen levels were comparable, thereby suggesting that factors indicative of the clotting of blood were depleted by the addition of the molecular sieve containing partially re-hydrated zeolite.
- Varying amounts of a molecular sieve containing zeolite were added to 1 milliliter (ml) samples of normal pooled plasma.
- mg milligram
- C. centigrade
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 10/939,869, filed Sep. 13, 2004, which claims the benefit of U.S. Provisional Patent Application No. 60/502,571 filed Sep. 12, 2003, entitled “Blood Clotting Compositions and Wound Dressings,” to Francis X. Hursey, the contents of these priority documents are incorporated herein by reference.
- The present invention relates to blood clotting devices (also referred to as hemostatic agents) and methods of controlling bleeding and, more particularly, to blood clotting materials and compositions for use as bleeding control devices.
- Blood is a liquid tissue that includes red cells, white cells, corpuscles, and platelets dispersed in a liquid phase. The liquid phase is plasma, which includes acids, lipids, solublized electrolytes, and proteins. The proteins are suspended in the liquid phase and can be separated out of the liquid phase by any of a variety of methods such as filtration, centrifugation, electrophoresis, and immunochemical techniques. One particular protein suspended in the liquid phase is fibrinogen. When bleeding occurs, the fibrinogen reacts with water and thrombin (an enzyme) to form fibrin, which is insoluble in blood and polymerizes to form clots.
- In a wide variety of circumstances, animals, including humans, can be wounded. Often bleeding is associated with such wounds. In some instances, the wound and the bleeding are minor, and normal blood clotting functions in addition to the application of simple first aid are all that is required. Unfortunately, however, in other circumstances, substantial bleeding can occur. These situations usually require specialized equipment and materials as well as personnel trained to administer appropriate aid. If such aid is not readily available, excessive blood loss can occur. When bleeding is severe, sometimes the immediate availability of equipment and trained personnel is still insufficient to stanch the flow of blood in a timely manner.
- Moreover, severe wounds can often be inflicted in very remote areas or in situations, such as on a battlefield, where adequate medical assistance is not immediately available. In these instances, it is important to stop bleeding, even in less severe wounds, long enough to allow the injured person or animal to receive medical attention.
- In an effort to address the above-described problems, materials have been developed for controlling excessive bleeding in situations where conventional aid is unavailable or less than optimally effective. Although these materials have been shown to be somewhat successful, they are not effective enough for traumatic wounds and tend to be expensive. Furthermore, these materials are sometimes ineffective in all situations and can be difficult to apply as well as remove from a wound. Additionally, or alternatively, they can produce undesirable side effects.
- Compositions for promoting the formation of clots in blood have also been developed. Such compositions generally comprise zeolites and binders. In a typical zeolite/binder composition, the water content is estimated to be about 1.54% or less. The water content is estimated by measuring the mass of material before and after heating at 550 degrees C. (Loss on Ignition (LOI) at 550 degrees C.). Higher temperatures are sometimes used for LOI calculations, but procedures that utilize these higher temperatures increase the loss of chemical compounds other than water.
- Based on the foregoing, it is a general object of the present invention to provide a bleeding control device that overcomes or improves upon the prior art.
- In general, the basic material forming the wound dressing, covering, and/or application system of the present invention for use in blood coagulation comprises a combination of one or more components selected from the group consisting of clay materials, a molecular sieve material, principally zeolite, and inorganic oxide materials. Although the actual process which enables the wound dressing, covering, and/or application system of the present invention to effectively coagulate flowing blood is unknown, it is believed that the molecular sieve material selectively absorbs small molecules, such as water, from the blood. Due to the absorption of the water molecules, it is believed that the rate of blood clotting is increased.
- According to one aspect of the present invention, a composition for promoting the formation of clots in blood comprises a zeolite and a binder. In such a composition, the moisture content of the zeolite is adjusted by drying, re-hydrating, or a combination of drying and re-hydrating such that the zeolite has a specific moisture content. Alternatively, the composition may be fully saturated with water and subsequently dried to a specific water content. In the drying of the zeolite, the bound water is removed to allow the crystalline structure of the zeolite to remain intact. In the re-hydration of the zeolite, the most active adsorption sites are hydrated first and then less active sites are hydrated. As the zeolite's degree of hydration increases, the heat of hydration decreases. More specifically, when the composition is applied to the blood, water in the blood is adsorbed by the zeolite. Upon adsorption of this water, heat is generated. At higher levels of hydration (hydration of the zeolite prior to its application to blood), less heat is generated when the composition is applied to blood. Thus, when the composition is applied to blood directly at a wound site, the amount of heat transferred to the tissue surrounding the wound site is reduced.
- According to another aspect of the present invention, a method of forming a blood-clotting composition comprises the steps of providing a zeolite in hydrated form and adjusting a moisture content of the zeolite to have a specific moisture content such that upon application of the composition to a wound, a heat of hydration is reduced and a heat transferred to the wound is reduced.
- According to another aspect of the present invention, a method of clotting blood flowing from a wound comprises the steps of applying a zeolite to the wound and maintaining the zeolite in contact with the wound for a predetermined amount of time, the zeolite having an adjusted moisture content and being capable of producing a controllable exothermic effect on the wound.
- One advantage of the present invention is that it is easily applied to an open wound. It can be readily removed from sterilized packaging and deposited directly at the points from which blood emanates to dress the wound.
- Another advantage of the present invention is that the rate of water adsorption is dramatically reduced as the degree of hydration increases from about 0.1% to about 4%. After about 4%, the rate of adsorption is slower. Also, after about 4%, the rate of adsorption changes more slowly. In application of the composition to promote the clotting of blood, slower water adsorption is advantageous for two reasons. First, the humidity and temperature of the packaging environment has less of an affect, thereby allowing material to be exposed to the environment for a longer period of time without significantly changing the pre-hydration level. Second, the slower rate of water adsorption allows the heat of hydration to be dissipated over a longer period of time. Therefore, the composition is heated to a lower maximum temperature. Thus, less heat is transferred to the tissue of a wound without losing product efficacy (formation of clots in blood).
- The present invention is able to effectively clot traumatic bleeding of wounds better than other available methods for treating similar wounds. For example, in a lethal femoral swine model in which several blood clotting materials were evaluated, the material of the present invention was the only material proven to have a morbidity rate of 0% including a standard pressure dressing.
- By employing the present invention, all of the difficulties and drawbacks found in the prior art have been eliminated, and a highly effective, reasonably priced, easily used wound dressing, covering, and/or application system is realized. In accordance with the present invention, the wound dressing, covering, and/or application system generally comprises, in its principal basic form, a unique composition or formulation which is easily applied to an open wound and rapidly and effectively promotes the clotting rate of any flowing blood. In this way, blood emanating from the open wound coagulates or clots in a rapid or accelerated manner.
- In its principal form, the wound dressing, coverings, and/or application system of the present invention comprises a molecular sieve material, which preferably consists of zeolite, in combination with a suitable binder in a sterilized form enabling its application directly to an open wound. Although the wound treatment material may be applied directly to the open wound, as the sole component for inducing blood coagulation, it is preferable that the wound or opening is also treated with sterilized dressings, such as gauze, pads, multiple layer covers, films, permeable bandages, and the like. In this way, the rate of blood clotting is increased and the rate of blood loss from the wound is rapidly reduced.
- In general, the basic material forming the wound dressing, covering, and/or application system of the present invention for use in blood coagulation comprises a combination of one or more components selected from the group consisting of clay materials, a molecular sieve material, principally zeolite, and inorganic oxide materials. Although the actual process which enables the wound dressing, covering, and/or application system of the present invention to effectively coagulate flowing blood is unknown, it is believed that the molecular sieve material selectively absorbs small molecules, such as water, from the blood. Due to the absorption of the water molecules, it is believed that the rate of blood clotting is increased.
- In addition, other factors such as the production of heat and the presence of Ca ions in the inorganic oxide materials are believed to contribute to the efficacy of the compositions of the present invention in providing the desired rapid stoppage wound bleeding and promotion of blood coagulation. Although the precise mechanism or process by which the compositions of the present invention provided the desired results, it has been found that the compositions detailed herein provide a highly effective blood coagulation product capable of being quickly and easily applied to any desired wound site for achieving rapid termination of blood flow.
- In this regard, the present invention is capable of being employed in a wide variety of applications and/or uses. One principal use is in trauma situations, such as car accidents, where large open wounds may be produced with excessive blood loss. In addition, similar conditions are often found in military applications, particularly during armed conflicts. Furthermore, numerous other applications benefit from the use of the present invention, such as use in a surgical environment as well as in veterinary applications where animal bleeding occurs due to accidents or surgical operations.
- In order to provide the desired water absorption capabilities, the molecular sieve material or zeolite forming a part of the composition of this invention is typically dehydrated in its final form, usually to a hydration level of about 0.5%. In addition, the application of the dehydrated zeolite material to the open wound produces an exothermic reaction, which often assists with the promotion of the coagulation of the blood. However, in some instances, the exothermic reaction is substantial, causing damage to the surrounding tissue.
- In order to eliminate any potential harm being caused to surrounding tissue, as well assuring the creation of a wound dressing, covering, and/or application system which achieves all of the desired goals, it has been found that the efficacy provided by the molecular sieve material/zeolite is enhanced by rehydrating the molecular sieve material/zeolite to a hydration level ranging between about 1% and 15%. In addition, it has been found that this hydration level more preferably ranges between about 2% and 8%.
- By rehydrating the molecular sieve material/zeolite to a level ranging between about 1% and 15%, it has been found that the exothermia cause by the reaction of the molecular sieve material/zeolite with the blood flowing from an open wound is reduced to a level which virtually eliminates any potential damage to the surrounding tissue. In addition, the rate of blood coagulation is substantially unaffected, continuing to provide the desired rapid stoppage of blood flow by clotting the blood and effectively cauterizing the wound area.
- Disclosed herein are compositions and methods directed to the clotting of blood and the forming of blood clotting compositions. The compositions generally include molecular sieves for minimizing or stopping bleeding by absorbing at least portions of the liquid phases of blood, thereby promoting clotting. The methods generally include the application of molecular sieves to bleeding wounds to provide dressings and removing components of the blood to facilitate the formation of clots.
- In one embodiment of the present invention, a molecular sieve comprises a zeolite and a binder. As used herein, the term “zeolite” refers to a crystalline form of aluminosilicate that may include several ionic species including sodium and calcium moieties. The preferred molecular structure of the zeolite is referred to as an “A-type” crystal. As used herein, the term “A-type crystal” is intended to indicate a crystal having a cubic crystalline structure and round holes. The zeolite may be ion-exchanged to include a specific cation, for example, calcium, sodium, potassium, silver, or magnesium, or any combination of the foregoing. Suitable zeolites for use in the applications disclosed herein are also preferably nanoporous so as to provide increased surface areas. As used herein, the term “nanoporous” is intended to indicate an average pore diameter of about 3 angstroms to about 5 angstroms.
- In another embodiment of the present invention, the zeolite comprises irregularly-shaped granular material that is prepared by grinding larger particles and then selecting material that will pass through a 16 mesh sieve screen but will not pass through a 40 mesh sieve screen. The resulting zeolite is a composition of irregular granules that range in size from 0.4 millimeters (mm) in diameter to 0.8 mm in diameter.
- Zeolites for use in the disclosed applications may be naturally occurring or synthetically produced. Numerous varieties of naturally occurring zeolites are found as deposits in sedimentary environments as well as in other places. Naturally occurring zeolites that may be applicable to the compositions and methods described herein include, but are not limited to, analcite, chabazite, heulandite, natrolite, stilbite, and thomosonite. Synthetically produced zeolites that may also find use in the compositions and methods described herein are generally produced by processes in which rare earth oxides are substituted by silicates, alumina, or alumina in combination with alkali or alkaline earth metal oxides.
- The binder is preferably clay-based and may further include fillers (e.g., aluminum sulfate) or thickening agents that facilitate the selective application of the zeolite in various forms (e.g., as a paste, gel, powder, or erodible solid member). Natural clays that may provide suitable bases include, but are not limited to, kaolin, kaolinite, bentonite, montmorillonite, combinations of the foregoing clays, and the like. Modified clays such as polyorganosilcate graft polymers may also provide suitable bases.
- In the preparation of the zeolite for a blood clotting composition, the moisture content of the zeolite is adjusted by drying, re-hydrating, or a combination of drying and re-hydrating the zeolite such that the zeolite has a specific moisture content. A fully hydrated zeolite has a moisture content of about 20 weight percent (wt. %). Drying of the zeolite may be effected by the application of heat. Upon heating, adsorbed water bound in the crystalline structure is driven off without altering the structure itself or detracting from its integrity. The dried zeolite may then be re-hydrated. Upon drying or drying and re-hydrating, the zeolite contains about 1.55 wt. % to about 10 wt. % moisture, and preferably about 1.55 wt. % to about 4 wt. % moisture. Alternatively, the drying process can be stopped before the material is completely dehydrated. The final hydration of the material can be controlled by monitoring and controlling the temperature of zones of a drying apparatus in which the material is dried.
- The hydrated zeolite material also generates less heat upon being fully-saturated with water in the application of the zeolite to the blood. In particular, the heat of hydration is inversely proportional to the moisture content. Therefore, a zeolite hydrated to a moisture content of 4 wt. % will generate measurably less heat than a zeolite that has been fully dehydrated to less than 0.1 wt. %. Both materials, however, will be fully-saturated with water upon application to a bleeding wound. Thus, when applied to a bleeding wound under conditions of actual use, the exothermic effects and heat transferred to the wound are reduced. Therefore, upon application of the composition of the present invention to a bleeding wound, less heat is transferred to the tissue of the wound.
- As stated above, upon treating wounds with the present invention, the remaining blood, which includes cells, corpuscles, platelets, and plasma, is concentrated. The platelets aggregate and interact with collagen, phospholipids, and lipid-containing proteins in the plasma. The aggregation of the platelets provide nuclei upon which fibrin binds to form a clot. Cells from the blood subsequently combine with the clot to form a mass. When blood emanates from the wound, the formation of the mass from the clot causes the flow of blood to cease, thereby eliminating further loss of blood. The blood pressure will often noticeably increase upon application of the present invention due to cessation of blood loss.
- A molecular sieve containing partially re-hydrated zeolite was added to normal pooled plasma. Upon completion of the ensuing reaction, the plasma was separated into two phases, namely, a heavy phase and a supernatant phase. The heavy phase included the typical blood plasma components as well as the reacted zeolite. The supernatant phase was tested to determine the levels of PT, aPTT, and fibrinogen, where “PT” is prothrombin time and “aPTT” is activated partial thromboplastin time. As used herein, PT and aPPT are assays that provide time values that are compared to other samples or to a hemotological standard. The time values are used indirectly to suggest the levels of clotting factors present in pooled plasma. A control comprising serum was also tested to determine the levels of the same components. In a comparison of the supernatant phase to the control, it was noted that the PT, aPTT, and fibrinogen levels were comparable, thereby suggesting that factors indicative of the clotting of blood were depleted by the addition of the molecular sieve containing partially re-hydrated zeolite.
- Varying amounts of a molecular sieve containing zeolite were added to 1 milliliter (ml) samples of normal pooled plasma. In the first sample, 200 milligram (mg) of the molecular sieve was added and reacted, and a temperature increase of 9 centigrade (C.) degrees was observed. In the second sample, about 3.8 mg of the molecular sieve was added and reacted, and a temperature increase of less than 1 C. degree was observed.
- Although this invention has been shown and described with respect to the detailed embodiments thereof, it will be understood by those of skill in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed in the above detailed description, but that the invention will include all embodiments falling within the scope of the appended claims.
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/510,203 US20090299253A1 (en) | 2003-09-12 | 2009-07-27 | Blood clotting compositions and wound dressings |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50257103P | 2003-09-12 | 2003-09-12 | |
US10/939,869 US8252344B2 (en) | 2003-09-12 | 2004-09-13 | Partially hydrated hemostatic agent |
US12/510,203 US20090299253A1 (en) | 2003-09-12 | 2009-07-27 | Blood clotting compositions and wound dressings |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/939,869 Continuation US8252344B2 (en) | 2003-09-12 | 2004-09-13 | Partially hydrated hemostatic agent |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090299253A1 true US20090299253A1 (en) | 2009-12-03 |
Family
ID=34375268
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/939,869 Active 2028-01-31 US8252344B2 (en) | 2003-09-12 | 2004-09-13 | Partially hydrated hemostatic agent |
US12/510,203 Abandoned US20090299253A1 (en) | 2003-09-12 | 2009-07-27 | Blood clotting compositions and wound dressings |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/939,869 Active 2028-01-31 US8252344B2 (en) | 2003-09-12 | 2004-09-13 | Partially hydrated hemostatic agent |
Country Status (5)
Country | Link |
---|---|
US (2) | US8252344B2 (en) |
EP (1) | EP1667623B1 (en) |
AT (1) | ATE489062T1 (en) |
DE (1) | DE602004030264D1 (en) |
WO (1) | WO2005027834A2 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7968114B2 (en) | 2006-05-26 | 2011-06-28 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US8066874B2 (en) | 2006-12-28 | 2011-11-29 | Molycorp Minerals, Llc | Apparatus for treating a flow of an aqueous solution containing arsenic |
US8114433B2 (en) | 2006-05-26 | 2012-02-14 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
CN102366640A (en) * | 2011-10-14 | 2012-03-07 | 浙江安吉华埠实业有限公司 | Zeolite tourniquet bandage |
US8202532B2 (en) | 2006-05-26 | 2012-06-19 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US8252344B2 (en) | 2003-09-12 | 2012-08-28 | Z-Medica Corporation | Partially hydrated hemostatic agent |
US8252087B2 (en) | 2007-10-31 | 2012-08-28 | Molycorp Minerals, Llc | Process and apparatus for treating a gas containing a contaminant |
US8257731B2 (en) | 2005-02-09 | 2012-09-04 | Z-Medica Corporation | Devices and methods for the delivery of molecular sieve materials for the formation of blood clots |
US8349764B2 (en) | 2007-10-31 | 2013-01-08 | Molycorp Minerals, Llc | Composition for treating a fluid |
WO2013040080A1 (en) * | 2011-09-12 | 2013-03-21 | Protege Biomedical, Llc | Composition and dressing for wound treatment |
US8475658B2 (en) | 2003-01-29 | 2013-07-02 | Molycorp Minerals, Llc | Water purification device for arsenic removal |
US8858969B2 (en) | 2010-09-22 | 2014-10-14 | Z-Medica, Llc | Hemostatic compositions, devices, and methods |
US8938898B2 (en) | 2006-04-27 | 2015-01-27 | Z-Medica, Llc | Devices for the identification of medical products |
US9072806B2 (en) | 2012-06-22 | 2015-07-07 | Z-Medica, Llc | Hemostatic devices |
US9233863B2 (en) | 2011-04-13 | 2016-01-12 | Molycorp Minerals, Llc | Rare earth removal of hydrated and hydroxyl species |
US9975787B2 (en) | 2014-03-07 | 2018-05-22 | Secure Natural Resources Llc | Removal of arsenic from aqueous streams with cerium (IV) oxide compositions |
US10959655B2 (en) | 2014-06-13 | 2021-03-30 | Kurin, Inc. | Catheter insertion device with blood analyzer |
US11744494B2 (en) | 2017-02-10 | 2023-09-05 | Kurin, Inc. | Blood contaminant sequestration device with one-way air valve and air-permeable blood barrier with closure mechanism |
US11832944B2 (en) | 2015-07-24 | 2023-12-05 | Kurin, Inc. | Blood sample optimization device |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005027808A1 (en) * | 2003-09-12 | 2005-03-31 | Z-Medica Corporation | Calcium zeolite hemostatic agent |
US8916208B2 (en) * | 2004-06-24 | 2014-12-23 | California Institute Of Technology | Aluminophosphate-based materials for the treatment of wounds |
EP1853326B1 (en) | 2005-02-15 | 2016-06-15 | Virginia Commonwealth University | Mineral technologies (mt) for acute hemostasis and for the treatment of acute wounds and chronic ulcers |
US20060211965A1 (en) * | 2005-03-16 | 2006-09-21 | Z-Medica, Llc | Device for the delivery of blood clotting materials to a wound site |
US9326995B2 (en) * | 2005-04-04 | 2016-05-03 | The Regents Of The University Of California | Oxides for wound healing and body repair |
EP1868621A1 (en) * | 2005-04-04 | 2007-12-26 | The Regents of the University of California | Inorganic materials for hemostatic modulation and therapeutic wound healing |
US20060282046A1 (en) * | 2005-04-13 | 2006-12-14 | Horn Jeffrey L | Device and method for subcutaneous delivery of blood clotting agent |
US20070104768A1 (en) * | 2005-11-07 | 2007-05-10 | Z-Medica Corporation | Devices for the delivery of molecular sieve materials for the formation of blood clots |
EP1810697A3 (en) * | 2005-11-07 | 2008-04-02 | Jeffrey L. Horn | Devices for the delivery of molecular sieve materials for the formation of blood clots |
US20070154510A1 (en) * | 2005-12-30 | 2007-07-05 | Wilcher Steve A | Adsorbent-Containing Hemostatic Devices |
US20070154509A1 (en) * | 2005-12-30 | 2007-07-05 | Wilcher Steve A | Adsorbent-Containing Hemostatic Devices |
DE102006006905A1 (en) * | 2006-02-09 | 2007-08-23 | Durtec Gmbh | Hemostatic agent |
DE102006006904A1 (en) * | 2006-02-09 | 2007-08-23 | Universität Rostock | New haemostatic agents and adhesives for medical applications |
US20070276308A1 (en) * | 2006-05-26 | 2007-11-29 | Huey Raymond J | Hemostatic agents and devices for the delivery thereof |
US20080063697A1 (en) * | 2006-09-08 | 2008-03-13 | Bedard Robert L | Use of Unactivated Calcium Exchanged Zeolites in Hemostatic Devices and Products |
US20080125686A1 (en) * | 2006-11-29 | 2008-05-29 | Denny Lo | Heat mitigating hemostatic agent |
US20080145455A1 (en) * | 2006-12-13 | 2008-06-19 | Bedard Robert L | Combination of Inorganic Hemostatic Agents with Other Hemostatic Agents |
US8703634B2 (en) * | 2007-02-21 | 2014-04-22 | The Regents Of The University Of California | Hemostatic compositions and methods of use |
WO2008157536A2 (en) * | 2007-06-21 | 2008-12-24 | Z-Medica Corporation | Hemostatic sponge and method of making the same |
US8202549B2 (en) | 2007-08-14 | 2012-06-19 | The Regents Of The University Of California | Mesocellular oxide foams as hemostatic compositions and methods of use |
US20090047366A1 (en) * | 2007-08-15 | 2009-02-19 | Bedard Robert L | Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants |
US20090162406A1 (en) * | 2007-09-05 | 2009-06-25 | Z-Medica Corporation | Wound healing with zeolite-based hemostatic devices |
US8883194B2 (en) * | 2007-11-09 | 2014-11-11 | Honeywell International, Inc. | Adsorbent-containing hemostatic devices |
US8795718B2 (en) * | 2008-05-22 | 2014-08-05 | Honeywell International, Inc. | Functional nano-layered hemostatic material/device |
WO2011066471A1 (en) | 2009-11-25 | 2011-06-03 | Loma Linda University Medical Center | Chitosan-based hemostatic textile |
WO2012008835A1 (en) * | 2010-07-16 | 2012-01-19 | Rhino Research Europe B.V. | Method for drying seed |
WO2014086893A1 (en) | 2012-12-04 | 2014-06-12 | Purmin Gmbh | Geopolymer hydrogels or suspensions and storage-stable granular mineral composites with colloidal portion, method for producing same and use thereof |
CA3109313A1 (en) | 2012-12-26 | 2014-07-03 | Societes Des Produits Nestle S.A. | Low density coated animal litter compositions |
EP3122300B1 (en) | 2014-03-24 | 2020-03-11 | Datt Life Sciences Private Limited | A ready to use biodegradable and biocompatible device and a method of preparation thereof |
US9259357B2 (en) | 2014-04-16 | 2016-02-16 | Loma Linda University | Composition, preparation, and use of chitosan shards for biomedical applications |
BR112018007631A2 (en) | 2015-10-23 | 2018-11-06 | Nestec Sa | low density pet sands and methods of manufacturing and using these pet sands |
CN109999216B (en) * | 2019-05-20 | 2020-05-22 | 北京化工大学 | Trauma hemostatic sponge and preparation method and application thereof |
Citations (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2969145A (en) * | 1956-05-07 | 1961-01-24 | Johnson & Johnson | Packaged adhesive bandage |
US3122140A (en) * | 1962-03-29 | 1964-02-25 | Johnson & Johnson | Flexible absorbent sheet |
US3181231A (en) * | 1963-08-06 | 1965-05-04 | Union Carbide Corp | Molecular sieve-metal agglomerates and their preparation |
US3189227A (en) * | 1962-12-07 | 1965-06-15 | American Home Prod | Fluid dispenser |
US3366578A (en) * | 1964-12-07 | 1968-01-30 | Universal Oil Prod Co | Zeolite and method for making the improved zeolite |
US3386802A (en) * | 1967-07-28 | 1968-06-04 | Universal Oil Prod Co | Method for preparing spherically-shaped crystalline zeolite particles |
US3698392A (en) * | 1971-04-21 | 1972-10-17 | Kewanee Oil Co | Topical dressing |
US3723352A (en) * | 1971-01-25 | 1973-03-27 | Air Prod & Chem | Supported silver catalysts |
US4373519A (en) * | 1981-06-26 | 1983-02-15 | Minnesota Mining And Manufacturing Company | Composite wound dressing |
US4374044A (en) * | 1981-01-19 | 1983-02-15 | General Motors Corporation | Cordierite bead catalyst support and method of preparation |
US4379143A (en) * | 1980-12-05 | 1983-04-05 | Pq Corporation | Topical liquid or ointment |
US4435512A (en) * | 1980-11-28 | 1984-03-06 | Nippondenso Co., Ltd. | Process for producing cordierite ceramic products |
US4460642A (en) * | 1981-06-26 | 1984-07-17 | Minnesota Mining And Manufacturing Company | Water-swellable composite sheet of microfibers of PTFE and hydrophilic absorptive particles |
US4514510A (en) * | 1983-09-08 | 1985-04-30 | American Colloid Company | Hydrogen enriched water swellable clay having reduced acid demand and stable at low pH |
US4524064A (en) * | 1982-05-26 | 1985-06-18 | Nippon Oil Company, Limited | Wound-covering materials |
US4525410A (en) * | 1982-08-24 | 1985-06-25 | Kanebo, Ltd. | Particle-packed fiber article having antibacterial property |
US4569343A (en) * | 1982-09-30 | 1986-02-11 | Firma Carl Freudenberg | Skin application medicament |
US4651725A (en) * | 1985-04-18 | 1987-03-24 | Unitika Ltd. | Wound dressing |
US4717735A (en) * | 1986-04-10 | 1988-01-05 | European Body Wrap, Inc. | Composition for body wrap |
US4728323A (en) * | 1986-07-24 | 1988-03-01 | Minnesota Mining And Manufacturing Company | Antimicrobial wound dressings |
US4748978A (en) * | 1984-09-27 | 1988-06-07 | Kamp Herman F | Therapeutic dressing having mineral components |
US4822349A (en) * | 1984-04-25 | 1989-04-18 | Hursey Francis X | Method of treating wounds |
US4828832A (en) * | 1983-09-07 | 1989-05-09 | Laboratorios Biochemie De Mexico | Method of manufacturing a composition for treating skin lesions |
US4828081A (en) * | 1988-03-04 | 1989-05-09 | Samsonite Corporation | Luggage identification system |
US4911898A (en) * | 1983-01-21 | 1990-03-27 | Kanebo Limited | Zeolite particles retaining silver ions having antibacterial properties |
US5486195A (en) * | 1993-07-26 | 1996-01-23 | Myers; Gene | Method and apparatus for arteriotomy closure |
US5502042A (en) * | 1994-07-22 | 1996-03-26 | United States Surgical Corporation | Methods and compositions for treating wounds |
US5597581A (en) * | 1993-07-09 | 1997-01-28 | Karl W. An Haak | Chitosan foil for wound sealing and process for its preparation |
US5599578A (en) * | 1986-04-30 | 1997-02-04 | Butland; Charles L. | Technique for labeling an object for its identification and/or verification |
US5716337A (en) * | 1992-06-10 | 1998-02-10 | Johnson & Johnson Medical, Inc. | Absorbent product |
US5725551A (en) * | 1993-07-26 | 1998-03-10 | Myers; Gene | Method and apparatus for arteriotomy closure |
US5728451A (en) * | 1994-11-28 | 1998-03-17 | Langley; John D. | Breathable non-woven composite viral penetration barrier fabric and fabrication process |
US5766715A (en) * | 1995-04-10 | 1998-06-16 | Michel Garçonnet | Compact disposable packing that forms a kit |
US5801116A (en) * | 1995-04-07 | 1998-09-01 | Rhodia Inc. | Process for producing polysaccharides and their use as absorbent materials |
US5855570A (en) * | 1995-04-12 | 1999-01-05 | Scherson; Daniel A. | Oxygen producing bandage |
US5916511A (en) * | 1997-08-19 | 1999-06-29 | Ngk Insulators, Ltd. | Production method of cordierite ceramic honeycomb structure |
US6037280A (en) * | 1997-03-21 | 2000-03-14 | Koala Konnection | Ultraviolet ray (UV) blocking textile containing particles |
US6060461A (en) * | 1999-02-08 | 2000-05-09 | Drake; James Franklin | Topically applied clotting material |
US6187347B1 (en) * | 2000-02-09 | 2001-02-13 | Ecosafe, Llc. | Composition for arresting the flow of blood and method |
US6203512B1 (en) * | 1999-06-28 | 2001-03-20 | The Procter & Gamble Company | Method for opening a packaging device and retrieving an interlabial absorbent article placed therein |
US6251423B1 (en) * | 1995-05-20 | 2001-06-26 | Smith & Nephew Plc | Sterilizable paste product for topical application |
US6372333B1 (en) * | 1998-02-25 | 2002-04-16 | Rengo Co., Ltd. | Composition containing inorganic porous crystals-hydrophilic macromolecule composite and product made therefrom |
US20020077653A1 (en) * | 1998-04-08 | 2002-06-20 | Hudson John Overton | Hemostatic system for body cavities |
US20030018357A1 (en) * | 2001-05-09 | 2003-01-23 | Luthra Ajay K. | Wound closure system and methods |
US6523778B2 (en) * | 2000-06-29 | 2003-02-25 | The Night Fun Co., Llc | Illuminated emergency signaling device and flying balloon |
US6573419B2 (en) * | 2000-08-25 | 2003-06-03 | Sody Naimer | Elastic adhesive wound dressing for control of bleeding and for dressing bleeding wounds |
US20040005350A1 (en) * | 2002-06-28 | 2004-01-08 | Looney Dwayne Lee | Hemostatic wound dressings and methods of making same |
US6685227B2 (en) * | 2000-07-14 | 2004-02-03 | Safer Sleep Limited | Label, a label system and method |
US20040038893A1 (en) * | 2002-06-07 | 2004-02-26 | Dyax Corp. | Prevention and reduction of blood loss |
US6700032B1 (en) * | 1996-03-07 | 2004-03-02 | Leatherite Pty Limited | Wound care management |
US6701649B1 (en) * | 2002-12-12 | 2004-03-09 | Gunter Brosi | Combat identification marker |
US6745720B2 (en) * | 2002-10-29 | 2004-06-08 | Cycle Group Limited Of Delaware | Clumping animal litter and method of making same |
US20040121438A1 (en) * | 2002-12-19 | 2004-06-24 | Stephen Quirk | Wound care compositions |
US20050023956A1 (en) * | 2003-07-29 | 2005-02-03 | Samsung Sdi Co., Ltd. | Flat panel display |
US20050058721A1 (en) * | 2003-09-12 | 2005-03-17 | Hursey Francis X. | Partially hydrated hemostatic agent |
US20050070693A1 (en) * | 2003-07-31 | 2005-03-31 | Immunomedics, Inc. | Therapy using anti-CD-19 antibodies |
US20050074505A1 (en) * | 2003-09-12 | 2005-04-07 | Hursey Francis X. | Calcium zeolite hemostatic agent |
US6890177B2 (en) * | 2002-12-02 | 2005-05-10 | Centrix, Inc. | Method and device for the retraction and hemostasis of tissue during crown and bridge procedures |
US20050107826A1 (en) * | 2003-08-14 | 2005-05-19 | Zhu Yong H. | Vascular wound closure device and method |
US20050118230A1 (en) * | 2003-10-22 | 2005-06-02 | Encelle, Inc. | Methods and compositions for regenerating connective tissue |
US20050119112A1 (en) * | 2002-01-22 | 2005-06-02 | Zeochem, Llc | Process for production of molecular sieve adsorbent blends |
US20050137512A1 (en) * | 2003-12-23 | 2005-06-23 | Campbell Todd D. | Wound dressing and method for controlling severe, life-threatening bleeding |
US20050143689A1 (en) * | 2003-08-17 | 2005-06-30 | Ramsey Maynard Iii | Internal compression tourniquet catheter system and method for wound track navigation and hemorrhage control |
US6998510B2 (en) * | 2002-02-04 | 2006-02-14 | Damage Control Surgical Technologies, Inc. | Method and apparatus for improved hemostasis and damage control operations |
US20060034935A1 (en) * | 2004-07-22 | 2006-02-16 | Pronovost Allan D | Compositions and methods for treating excessive bleeding |
US20060078628A1 (en) * | 2004-10-09 | 2006-04-13 | Karl Koman | Wound treating agent |
US20060116635A1 (en) * | 2004-11-29 | 2006-06-01 | Med Enclosure L.L.C. | Arterial closure device |
US20060121101A1 (en) * | 2004-12-08 | 2006-06-08 | Ladizinsky Daniel A | Method for oxygen treatment of intact skin |
US20060141060A1 (en) * | 2004-12-27 | 2006-06-29 | Z-Medica, Llc | Molecular sieve materials having increased particle size for the formation of blood clots |
US20060141018A1 (en) * | 2001-12-31 | 2006-06-29 | Crosslink-D, Incorporated, A Delaware Corporation | Hemostatic compositions and methods for controlling bleeding |
US20070016152A1 (en) * | 2005-07-14 | 2007-01-18 | Boehringer Laboratories, Inc. | System for treating a wound with suction and method detecting loss of suction |
US20070031515A1 (en) * | 2005-04-04 | 2007-02-08 | Stucky Galen D | Inorganic materials for hemostatic modulation and therapeutic wound healing |
US20070065491A1 (en) * | 2005-02-09 | 2007-03-22 | Z-Medica Corporation | Devices and methods for the delivery of blood clotting materials to bleeding wounds |
US20070104768A1 (en) * | 2005-11-07 | 2007-05-10 | Z-Medica Corporation | Devices for the delivery of molecular sieve materials for the formation of blood clots |
US20070104792A1 (en) * | 2005-09-13 | 2007-05-10 | Elan Pharma International, Limited | Nanoparticulate tadalafil formulations |
US20070276345A1 (en) * | 2006-05-26 | 2007-11-29 | Raymond Huey | Clay-based hemostatic agents and devices for the delivery thereof |
US20080027365A1 (en) * | 2006-06-01 | 2008-01-31 | Huey Raymond J | Hemostatic device with oxidized cellulose pad |
US20080085300A1 (en) * | 2006-10-06 | 2008-04-10 | Z-Medica Corporation | Hemostatic compositions and method of manufacture |
US20080097271A1 (en) * | 2006-10-20 | 2008-04-24 | Z-Medica Corporation | Devices and methods for the delivery of hemostatic agents to bleeding wounds |
US7371403B2 (en) * | 2002-06-14 | 2008-05-13 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
US20080125686A1 (en) * | 2006-11-29 | 2008-05-29 | Denny Lo | Heat mitigating hemostatic agent |
US20090008261A1 (en) * | 2005-03-03 | 2009-01-08 | Cambridge Enterprise Limited | Oxygen Generation Apparatus and Method |
US20090018479A1 (en) * | 2002-06-14 | 2009-01-15 | Hemcon Medical Technologies, Inc. | Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chistosan |
US20090043268A1 (en) * | 2007-08-06 | 2009-02-12 | Eddy Patrick E | Wound treatment system and suction regulator for use therewith |
US20090047366A1 (en) * | 2007-08-15 | 2009-02-19 | Bedard Robert L | Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants |
US20090053288A1 (en) * | 2007-08-20 | 2009-02-26 | Eskridge Jr E Stan | Hemostatic woven fabric |
US20090076475A1 (en) * | 2005-11-09 | 2009-03-19 | Oxysure Systems Inc. | Method and apparatus for delivering therapeutic oxygen treatments |
US20090112170A1 (en) * | 2007-10-26 | 2009-04-30 | Electrochemical Oxygen Concepts, Inc | Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability |
US20090123525A1 (en) * | 2007-11-09 | 2009-05-14 | Bedard Robert L | Adsorbent-Containing Hemostatic Devices |
US20100035045A1 (en) * | 2008-01-21 | 2010-02-11 | Imerys Pigments, Inc. | Fibers comprising at least one filler and processes for their production |
US20110015565A1 (en) * | 2009-07-15 | 2011-01-20 | Hursey Francis X | Gas dispenser with therapeutic agent |
US20110059287A1 (en) * | 2008-01-21 | 2011-03-10 | Imerys Pigments, Inc. | Fibers comprising at least one filler, processes for their production, and uses thereof |
US20110064785A1 (en) * | 2007-12-06 | 2011-03-17 | Nanosys, Inc. | Nanostructure-Enhanced Platelet Binding and Hemostatic Structures |
US20120004636A1 (en) * | 2010-07-02 | 2012-01-05 | Denny Lo | Hemostatic fibrous material |
US20120070470A1 (en) * | 2010-09-22 | 2012-03-22 | Z-Medica Corporation | Hemostatic compositions, devices, and methods |
US8383148B2 (en) * | 2006-05-26 | 2013-02-26 | Z-Medica, Llc | Clay-based hemostatic agents and devices for the delivery thereof |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2688586A (en) | 1950-03-17 | 1954-09-07 | Johnson & Johnson | Improved hemostatic alginic surgical dressings and method of making |
US3550593A (en) | 1967-02-02 | 1970-12-29 | Jack W Kaufman | Therapeutic apparatus |
US3538508A (en) | 1968-08-08 | 1970-11-10 | Samuel Young | Combination pillow and crash helmet |
US3979335A (en) * | 1974-12-27 | 1976-09-07 | Georgy Anatolievich Golovko | Process for the preparation of synthetic zeolites |
NZ209534A (en) | 1983-09-30 | 1987-01-23 | Surgikos Inc | Antimicrobial fabric for surgical drape |
US4626550A (en) * | 1985-01-14 | 1986-12-02 | Pq Corporation | Zeolite for personal care products |
US4631845A (en) | 1985-05-17 | 1986-12-30 | Intermec Corporation | Luggage tag |
US4938958A (en) | 1986-12-05 | 1990-07-03 | Shinagawa Fuel Co., Ltd. | Antibiotic zeolite |
JPH0618899B2 (en) | 1987-06-30 | 1994-03-16 | 品川燃料株式会社 | Film containing antibacterial zeolite |
JPH0245040A (en) | 1988-08-03 | 1990-02-15 | Terumo Corp | Reduced pressure blood taking tube |
US4956350A (en) | 1988-08-18 | 1990-09-11 | Minnesota Mining And Manufacturing Company | Wound filling compositions |
US5140949A (en) * | 1989-09-19 | 1992-08-25 | Mobil Oil Corporation | Zeolite-clay composition and uses thereof |
JP2777279B2 (en) | 1990-10-08 | 1998-07-16 | 工業技術院長 | Wound dressing and method for producing the same |
US5146932A (en) | 1990-11-01 | 1992-09-15 | Mccabe Francis J | Elastic counterpressure garment |
GB2259858A (en) | 1991-08-21 | 1993-03-31 | Glanmor Thomas Williams | Odour adsorbing means |
US5474545A (en) | 1992-12-07 | 1995-12-12 | Chikazawa; Osamu | Diaper and/or sanitary napkin |
GB9317180D0 (en) * | 1993-08-18 | 1993-10-06 | Unilever Plc | Granular detergent compositions containing zeolite and process for their preparation |
JPH0877746A (en) | 1994-08-31 | 1996-03-22 | Sony Corp | Recording medium housing cassette and cassette keeping case and label adhered thereto |
DE69534647T2 (en) | 1994-09-19 | 2006-07-27 | Sekisui Kagaku Kogyo K.K. | CONTAINERS AND CARRIER FOR THE BLOOD TEST CONTAINING A BLOOD COMPONENT ADHESION INHIBITOR |
US5826543A (en) | 1995-01-20 | 1998-10-27 | Ralston Purina Company | Clumpable animal litter containing a dust reducing agent |
US5538500A (en) | 1995-02-08 | 1996-07-23 | Peterson; Donald A. | Postoperative wound dressing |
US5788682A (en) | 1995-04-28 | 1998-08-04 | Maget; Henri J.R. | Apparatus and method for controlling oxygen concentration in the vicinity of a wound |
GB2305993A (en) | 1995-10-03 | 1997-04-23 | British Nuclear Fuels Plc | An energy storage rotor with axial length compensating means |
US5696101A (en) | 1996-04-16 | 1997-12-09 | Eastman Chemical Company | Oxidized cellulose and vitamin E blend for topical hemostatic applications |
US5964239A (en) | 1996-05-23 | 1999-10-12 | Hewlett-Packard Company | Housing assembly for micromachined fluid handling structure |
GB2314842B (en) | 1996-06-28 | 2001-01-17 | Johnson & Johnson Medical | Collagen-oxidized regenerated cellulose complexes |
CA2213936C (en) | 1996-08-27 | 2002-01-29 | Rengo Co., Ltd. | Inorganic porous crystals-hydrophilic macromolecule composite |
US5834008A (en) | 1996-09-19 | 1998-11-10 | U.S. Biomaterials Corp. | Composition and method for acceleration of wound and burn healing |
USD386002S (en) | 1996-10-01 | 1997-11-11 | Hinkle Gerald F | Combined pouch for first aid safety kit with instruction card |
JPH10298824A (en) | 1997-04-22 | 1998-11-10 | Chisso Corp | Fiber and fibrous formed product using the same |
US5941897A (en) | 1997-05-09 | 1999-08-24 | Myers; Gene E. | Energy activated fibrin plug |
GB2326827B (en) | 1997-06-30 | 2002-02-20 | Johnson & Johnson Medical | Use of molecular sieves to promote wound healing |
US6159232A (en) | 1997-12-16 | 2000-12-12 | Closys Corporation | Clotting cascade initiating apparatus and methods of use and methods of closing wounds |
AU3065999A (en) | 1998-03-10 | 1999-09-27 | Children's Hospital Of Philadelphia, The | Compositions and methods for treatment of asthma |
US6086970A (en) | 1998-04-28 | 2000-07-11 | Scimed Life Systems, Inc. | Lubricious surface extruded tubular members for medical devices |
US6123925A (en) | 1998-07-27 | 2000-09-26 | Healthshield Technologies L.L.C. | Antibiotic toothpaste |
CN1181809C (en) | 1998-09-25 | 2004-12-29 | 花王株式会社 | Compositions for oral cavity |
US20020197302A1 (en) | 1998-11-12 | 2002-12-26 | Cochrum Kent C. | Hemostatic polymer useful for rapid blood coagulation and hemostasis |
JP3423261B2 (en) | 1999-09-29 | 2003-07-07 | 三洋電機株式会社 | Display device |
US6763373B2 (en) | 1999-10-13 | 2004-07-13 | Datahouse Labs, Inc. | Method and system for creating and sending handwritten or handdrawn messages |
US6450537B2 (en) | 2000-01-24 | 2002-09-17 | Polaroid Corporation | Self-service postage stamp assemblage |
KR100721752B1 (en) | 2000-01-24 | 2007-05-25 | 쿠라레 메디카루 가부시키가이샤 | Water-swellable polymer gel and process for preparing the same |
NZ522121A (en) * | 2000-04-28 | 2005-11-25 | Biolife L | Method of arresting blood flow comprising application of an oxyacid ferrate (IV) salt to the wound |
US6592888B1 (en) | 2000-05-31 | 2003-07-15 | Jentec, Inc. | Composition for wound dressings safely using metallic compounds to produce anti-microbial properties |
ATE460146T1 (en) | 2000-09-15 | 2010-03-15 | Bruder Healthcare Co | WOUND AND TREATMENT COMPRESS AND DRESSING |
AU2002211686A1 (en) * | 2000-10-13 | 2002-04-22 | On Site Gas Systems, Inc. | Bandage using molecular sieves |
ATE312579T1 (en) | 2001-01-31 | 2005-12-15 | Missak Kechichian | ABSORBENT PRODUCT |
CN1516595A (en) | 2001-03-19 | 2004-07-28 | Iomai公司 | Patch for transcutaneous immunization |
US20040166172A1 (en) | 2001-03-27 | 2004-08-26 | Coni Rosati | Bioctive tissue abrasives |
US6481134B1 (en) | 2001-04-02 | 2002-11-19 | Alicia Aledo | Tag for attaching to a garment having an attribute and identifying the attribute to a person unable to visually identify the attribute |
US6622856B2 (en) | 2001-04-25 | 2003-09-23 | Johnson & Johnson Consumer Companies, Inc. | Relief kit |
US7429252B2 (en) | 2001-12-12 | 2008-09-30 | Ogenix Corporation | Oxygen producing device for woundcare |
US20030175333A1 (en) | 2002-03-06 | 2003-09-18 | Adi Shefer | Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin |
US20030199922A1 (en) | 2002-04-22 | 2003-10-23 | Buckman James S. | Pneumatic pressure bandage for medical applications |
US20030212357A1 (en) | 2002-05-10 | 2003-11-13 | Pace Edgar Alan | Method and apparatus for treating wounds with oxygen and reduced pressure |
US20060193905A1 (en) | 2002-05-14 | 2006-08-31 | University Of Louisville Research Foundation, Inc. | Direct cellular energy delivery system |
US20040101546A1 (en) | 2002-11-26 | 2004-05-27 | Gorman Anne Jessica | Hemostatic wound dressing containing aldehyde-modified polysaccharide and hemostatic agents |
GB2393120A (en) | 2002-09-18 | 2004-03-24 | Johnson & Johnson Medical Ltd | Compositions for wound treatment |
JP3794365B2 (en) | 2002-10-04 | 2006-07-05 | 憲司 中村 | Warming deodorant sterilizing compound and heat retaining deodorizing sterilizing material |
JP3975944B2 (en) | 2003-02-27 | 2007-09-12 | 住友電気工業株式会社 | HOLDER FOR SEMICONDUCTOR OR LIQUID CRYSTAL MANUFACTURING DEVICE AND SEMICONDUCTOR OR LIQUID CRYSTAL MANUFACTURING DEVICE WITH THE SAME |
US7125821B2 (en) | 2003-09-05 | 2006-10-24 | Exxonmobil Chemical Patents Inc. | Low metal content catalyst compositions and processes for making and using same |
CA2545813C (en) | 2003-11-14 | 2011-01-04 | Shanghai Genomics, Inc. | The derivatives of pyridone and use thereof |
ATE534424T1 (en) | 2004-03-19 | 2011-12-15 | Abbott Lab | MULTIPLE MEDICINAL DELIVERY FROM A BALLOON AND A PROSTHESIS |
GB0407502D0 (en) | 2004-04-02 | 2004-05-05 | Inotec Amd Ltd | Hyperbaric dressing |
US20050248270A1 (en) | 2004-05-05 | 2005-11-10 | Eastman Kodak Company | Encapsulating OLED devices |
US8916208B2 (en) | 2004-06-24 | 2014-12-23 | California Institute Of Technology | Aluminophosphate-based materials for the treatment of wounds |
EP1853326B1 (en) | 2005-02-15 | 2016-06-15 | Virginia Commonwealth University | Mineral technologies (mt) for acute hemostasis and for the treatment of acute wounds and chronic ulcers |
US20060211965A1 (en) | 2005-03-16 | 2006-09-21 | Z-Medica, Llc | Device for the delivery of blood clotting materials to a wound site |
US20060211971A1 (en) | 2005-03-16 | 2006-09-21 | Z-Medica, Llc | Pillow for the delivery of blood clotting materials to a wound site |
US9326995B2 (en) | 2005-04-04 | 2016-05-03 | The Regents Of The University Of California | Oxides for wound healing and body repair |
US20060282046A1 (en) | 2005-04-13 | 2006-12-14 | Horn Jeffrey L | Device and method for subcutaneous delivery of blood clotting agent |
EP1714642A1 (en) | 2005-04-18 | 2006-10-25 | Bracco Research S.A. | Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery |
US8063264B2 (en) | 2005-08-26 | 2011-11-22 | Michael Spearman | Hemostatic media |
EP1810697A3 (en) | 2005-11-07 | 2008-04-02 | Jeffrey L. Horn | Devices for the delivery of molecular sieve materials for the formation of blood clots |
US20070142783A1 (en) | 2005-12-16 | 2007-06-21 | Huey Raymond J | Devices and methods for promoting the formation of blood clots at dialysis access sites |
US20070154509A1 (en) | 2005-12-30 | 2007-07-05 | Wilcher Steve A | Adsorbent-Containing Hemostatic Devices |
US20070154510A1 (en) | 2005-12-30 | 2007-07-05 | Wilcher Steve A | Adsorbent-Containing Hemostatic Devices |
US8409629B2 (en) | 2006-01-09 | 2013-04-02 | Jack Mentkow | Hemostatic agent composition and method of delivery |
US9474652B2 (en) | 2006-01-09 | 2016-10-25 | Jack Mentkow | Hemostatic agent delivery system |
US8277837B2 (en) | 2006-01-11 | 2012-10-02 | Entegrion, Inc. | Hemostatic textile |
US20070167971A1 (en) | 2006-01-17 | 2007-07-19 | Raymond Huey | Devices and methods for promoting the formation of blood clots in esophageal varices |
US8938898B2 (en) | 2006-04-27 | 2015-01-27 | Z-Medica, Llc | Devices for the identification of medical products |
US20070276308A1 (en) | 2006-05-26 | 2007-11-29 | Huey Raymond J | Hemostatic agents and devices for the delivery thereof |
US7968114B2 (en) | 2006-05-26 | 2011-06-28 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
MX2008015275A (en) | 2006-05-30 | 2009-02-06 | Elan Pharma Int Ltd | Nanoparticulate posaconazole formulations. |
CN1970090B (en) | 2006-09-14 | 2015-11-25 | 华东理工大学 | Nanometer mesoporous silicon based xerogel hemostatic material and its preparation method and application |
US9198995B2 (en) | 2006-09-20 | 2015-12-01 | Ore-Medix Llc | Conformable structured therapeutic dressing |
US8703634B2 (en) | 2007-02-21 | 2014-04-22 | The Regents Of The University Of California | Hemostatic compositions and methods of use |
US20080206134A1 (en) | 2007-02-22 | 2008-08-28 | Denny Lo | Radio-opaque hemostatic agents and devices and methods for the delivery thereof |
US20080254147A1 (en) | 2007-04-13 | 2008-10-16 | Z-Medica Corporation | Method of providing hemostasis in anti-coagulated blood |
US20080254146A1 (en) | 2007-04-13 | 2008-10-16 | Z-Medica Corporation | Method of providing hemostasis in anti-coagulated blood |
CN101104080B (en) | 2007-04-24 | 2011-06-22 | 深圳市鸿华投资有限公司 | Zeolite hemostatic dressings and preparation method and application thereof |
US20080319476A1 (en) | 2007-05-22 | 2008-12-25 | Ward Kevin R | Hemostatic mineral compositions and uses thereof |
WO2008157536A2 (en) | 2007-06-21 | 2008-12-24 | Z-Medica Corporation | Hemostatic sponge and method of making the same |
US20090162406A1 (en) | 2007-09-05 | 2009-06-25 | Z-Medica Corporation | Wound healing with zeolite-based hemostatic devices |
-
2004
- 2004-09-10 EP EP04783867A patent/EP1667623B1/en not_active Not-in-force
- 2004-09-10 DE DE602004030264T patent/DE602004030264D1/en active Active
- 2004-09-10 WO PCT/US2004/029812 patent/WO2005027834A2/en active Application Filing
- 2004-09-10 AT AT04783867T patent/ATE489062T1/en not_active IP Right Cessation
- 2004-09-13 US US10/939,869 patent/US8252344B2/en active Active
-
2009
- 2009-07-27 US US12/510,203 patent/US20090299253A1/en not_active Abandoned
Patent Citations (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2969145A (en) * | 1956-05-07 | 1961-01-24 | Johnson & Johnson | Packaged adhesive bandage |
US3122140A (en) * | 1962-03-29 | 1964-02-25 | Johnson & Johnson | Flexible absorbent sheet |
US3189227A (en) * | 1962-12-07 | 1965-06-15 | American Home Prod | Fluid dispenser |
US3181231A (en) * | 1963-08-06 | 1965-05-04 | Union Carbide Corp | Molecular sieve-metal agglomerates and their preparation |
US3366578A (en) * | 1964-12-07 | 1968-01-30 | Universal Oil Prod Co | Zeolite and method for making the improved zeolite |
US3386802A (en) * | 1967-07-28 | 1968-06-04 | Universal Oil Prod Co | Method for preparing spherically-shaped crystalline zeolite particles |
US3723352A (en) * | 1971-01-25 | 1973-03-27 | Air Prod & Chem | Supported silver catalysts |
US3698392A (en) * | 1971-04-21 | 1972-10-17 | Kewanee Oil Co | Topical dressing |
US4435512A (en) * | 1980-11-28 | 1984-03-06 | Nippondenso Co., Ltd. | Process for producing cordierite ceramic products |
US4379143A (en) * | 1980-12-05 | 1983-04-05 | Pq Corporation | Topical liquid or ointment |
US4374044A (en) * | 1981-01-19 | 1983-02-15 | General Motors Corporation | Cordierite bead catalyst support and method of preparation |
US4373519A (en) * | 1981-06-26 | 1983-02-15 | Minnesota Mining And Manufacturing Company | Composite wound dressing |
US4460642A (en) * | 1981-06-26 | 1984-07-17 | Minnesota Mining And Manufacturing Company | Water-swellable composite sheet of microfibers of PTFE and hydrophilic absorptive particles |
US4524064A (en) * | 1982-05-26 | 1985-06-18 | Nippon Oil Company, Limited | Wound-covering materials |
US4525410A (en) * | 1982-08-24 | 1985-06-25 | Kanebo, Ltd. | Particle-packed fiber article having antibacterial property |
US4569343A (en) * | 1982-09-30 | 1986-02-11 | Firma Carl Freudenberg | Skin application medicament |
US4911898A (en) * | 1983-01-21 | 1990-03-27 | Kanebo Limited | Zeolite particles retaining silver ions having antibacterial properties |
US4828832A (en) * | 1983-09-07 | 1989-05-09 | Laboratorios Biochemie De Mexico | Method of manufacturing a composition for treating skin lesions |
US4514510A (en) * | 1983-09-08 | 1985-04-30 | American Colloid Company | Hydrogen enriched water swellable clay having reduced acid demand and stable at low pH |
US4822349A (en) * | 1984-04-25 | 1989-04-18 | Hursey Francis X | Method of treating wounds |
US4748978A (en) * | 1984-09-27 | 1988-06-07 | Kamp Herman F | Therapeutic dressing having mineral components |
US4651725A (en) * | 1985-04-18 | 1987-03-24 | Unitika Ltd. | Wound dressing |
US4717735A (en) * | 1986-04-10 | 1988-01-05 | European Body Wrap, Inc. | Composition for body wrap |
US5599578A (en) * | 1986-04-30 | 1997-02-04 | Butland; Charles L. | Technique for labeling an object for its identification and/or verification |
US4728323A (en) * | 1986-07-24 | 1988-03-01 | Minnesota Mining And Manufacturing Company | Antimicrobial wound dressings |
US4828081A (en) * | 1988-03-04 | 1989-05-09 | Samsonite Corporation | Luggage identification system |
US5716337A (en) * | 1992-06-10 | 1998-02-10 | Johnson & Johnson Medical, Inc. | Absorbent product |
US5597581A (en) * | 1993-07-09 | 1997-01-28 | Karl W. An Haak | Chitosan foil for wound sealing and process for its preparation |
US5486195A (en) * | 1993-07-26 | 1996-01-23 | Myers; Gene | Method and apparatus for arteriotomy closure |
US5725551A (en) * | 1993-07-26 | 1998-03-10 | Myers; Gene | Method and apparatus for arteriotomy closure |
US5502042A (en) * | 1994-07-22 | 1996-03-26 | United States Surgical Corporation | Methods and compositions for treating wounds |
US5728451A (en) * | 1994-11-28 | 1998-03-17 | Langley; John D. | Breathable non-woven composite viral penetration barrier fabric and fabrication process |
US5801116A (en) * | 1995-04-07 | 1998-09-01 | Rhodia Inc. | Process for producing polysaccharides and their use as absorbent materials |
US5766715A (en) * | 1995-04-10 | 1998-06-16 | Michel Garçonnet | Compact disposable packing that forms a kit |
US5855570A (en) * | 1995-04-12 | 1999-01-05 | Scherson; Daniel A. | Oxygen producing bandage |
US6251423B1 (en) * | 1995-05-20 | 2001-06-26 | Smith & Nephew Plc | Sterilizable paste product for topical application |
US6700032B1 (en) * | 1996-03-07 | 2004-03-02 | Leatherite Pty Limited | Wound care management |
US6037280A (en) * | 1997-03-21 | 2000-03-14 | Koala Konnection | Ultraviolet ray (UV) blocking textile containing particles |
US5916511A (en) * | 1997-08-19 | 1999-06-29 | Ngk Insulators, Ltd. | Production method of cordierite ceramic honeycomb structure |
US6372333B1 (en) * | 1998-02-25 | 2002-04-16 | Rengo Co., Ltd. | Composition containing inorganic porous crystals-hydrophilic macromolecule composite and product made therefrom |
US20020077653A1 (en) * | 1998-04-08 | 2002-06-20 | Hudson John Overton | Hemostatic system for body cavities |
US6060461A (en) * | 1999-02-08 | 2000-05-09 | Drake; James Franklin | Topically applied clotting material |
US6203512B1 (en) * | 1999-06-28 | 2001-03-20 | The Procter & Gamble Company | Method for opening a packaging device and retrieving an interlabial absorbent article placed therein |
US6187347B1 (en) * | 2000-02-09 | 2001-02-13 | Ecosafe, Llc. | Composition for arresting the flow of blood and method |
US6523778B2 (en) * | 2000-06-29 | 2003-02-25 | The Night Fun Co., Llc | Illuminated emergency signaling device and flying balloon |
US6685227B2 (en) * | 2000-07-14 | 2004-02-03 | Safer Sleep Limited | Label, a label system and method |
US6573419B2 (en) * | 2000-08-25 | 2003-06-03 | Sody Naimer | Elastic adhesive wound dressing for control of bleeding and for dressing bleeding wounds |
US20030018357A1 (en) * | 2001-05-09 | 2003-01-23 | Luthra Ajay K. | Wound closure system and methods |
US20060141018A1 (en) * | 2001-12-31 | 2006-06-29 | Crosslink-D, Incorporated, A Delaware Corporation | Hemostatic compositions and methods for controlling bleeding |
US20050119112A1 (en) * | 2002-01-22 | 2005-06-02 | Zeochem, Llc | Process for production of molecular sieve adsorbent blends |
US6998510B2 (en) * | 2002-02-04 | 2006-02-14 | Damage Control Surgical Technologies, Inc. | Method and apparatus for improved hemostasis and damage control operations |
US20040038893A1 (en) * | 2002-06-07 | 2004-02-26 | Dyax Corp. | Prevention and reduction of blood loss |
US20090018479A1 (en) * | 2002-06-14 | 2009-01-15 | Hemcon Medical Technologies, Inc. | Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chistosan |
US7371403B2 (en) * | 2002-06-14 | 2008-05-13 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
US20040005350A1 (en) * | 2002-06-28 | 2004-01-08 | Looney Dwayne Lee | Hemostatic wound dressings and methods of making same |
US6745720B2 (en) * | 2002-10-29 | 2004-06-08 | Cycle Group Limited Of Delaware | Clumping animal litter and method of making same |
US6890177B2 (en) * | 2002-12-02 | 2005-05-10 | Centrix, Inc. | Method and device for the retraction and hemostasis of tissue during crown and bridge procedures |
US6701649B1 (en) * | 2002-12-12 | 2004-03-09 | Gunter Brosi | Combat identification marker |
US20040121438A1 (en) * | 2002-12-19 | 2004-06-24 | Stephen Quirk | Wound care compositions |
US20050023956A1 (en) * | 2003-07-29 | 2005-02-03 | Samsung Sdi Co., Ltd. | Flat panel display |
US20050070693A1 (en) * | 2003-07-31 | 2005-03-31 | Immunomedics, Inc. | Therapy using anti-CD-19 antibodies |
US20050107826A1 (en) * | 2003-08-14 | 2005-05-19 | Zhu Yong H. | Vascular wound closure device and method |
US20050143689A1 (en) * | 2003-08-17 | 2005-06-30 | Ramsey Maynard Iii | Internal compression tourniquet catheter system and method for wound track navigation and hemorrhage control |
US20050058721A1 (en) * | 2003-09-12 | 2005-03-17 | Hursey Francis X. | Partially hydrated hemostatic agent |
US20050074505A1 (en) * | 2003-09-12 | 2005-04-07 | Hursey Francis X. | Calcium zeolite hemostatic agent |
US20050118230A1 (en) * | 2003-10-22 | 2005-06-02 | Encelle, Inc. | Methods and compositions for regenerating connective tissue |
US20050137512A1 (en) * | 2003-12-23 | 2005-06-23 | Campbell Todd D. | Wound dressing and method for controlling severe, life-threatening bleeding |
US20060034935A1 (en) * | 2004-07-22 | 2006-02-16 | Pronovost Allan D | Compositions and methods for treating excessive bleeding |
US20060078628A1 (en) * | 2004-10-09 | 2006-04-13 | Karl Koman | Wound treating agent |
US20060116635A1 (en) * | 2004-11-29 | 2006-06-01 | Med Enclosure L.L.C. | Arterial closure device |
US20060121101A1 (en) * | 2004-12-08 | 2006-06-08 | Ladizinsky Daniel A | Method for oxygen treatment of intact skin |
US20090074880A1 (en) * | 2004-12-08 | 2009-03-19 | Ladizinsky Daniel A | Method for oxygen treatment of intact skin |
US20060141060A1 (en) * | 2004-12-27 | 2006-06-29 | Z-Medica, Llc | Molecular sieve materials having increased particle size for the formation of blood clots |
US20070065491A1 (en) * | 2005-02-09 | 2007-03-22 | Z-Medica Corporation | Devices and methods for the delivery of blood clotting materials to bleeding wounds |
US20130041332A1 (en) * | 2005-02-09 | 2013-02-14 | Z-Medica Corporation | Devices and methods for the delivery of blood clotting materials to bleeding wounds |
US20100121244A1 (en) * | 2005-02-09 | 2010-05-13 | Z-Medica Corporation | Devices and methods for the delivery of molecular sieve materials for the formation of blood clots |
US20090008261A1 (en) * | 2005-03-03 | 2009-01-08 | Cambridge Enterprise Limited | Oxygen Generation Apparatus and Method |
US20070031515A1 (en) * | 2005-04-04 | 2007-02-08 | Stucky Galen D | Inorganic materials for hemostatic modulation and therapeutic wound healing |
US20070016152A1 (en) * | 2005-07-14 | 2007-01-18 | Boehringer Laboratories, Inc. | System for treating a wound with suction and method detecting loss of suction |
US20070104792A1 (en) * | 2005-09-13 | 2007-05-10 | Elan Pharma International, Limited | Nanoparticulate tadalafil formulations |
US20070104768A1 (en) * | 2005-11-07 | 2007-05-10 | Z-Medica Corporation | Devices for the delivery of molecular sieve materials for the formation of blood clots |
US20090076475A1 (en) * | 2005-11-09 | 2009-03-19 | Oxysure Systems Inc. | Method and apparatus for delivering therapeutic oxygen treatments |
US8383148B2 (en) * | 2006-05-26 | 2013-02-26 | Z-Medica, Llc | Clay-based hemostatic agents and devices for the delivery thereof |
US20130079695A1 (en) * | 2006-05-26 | 2013-03-28 | Z-Medica, Llc | Hemostatic sponge |
US20120130296A1 (en) * | 2006-05-26 | 2012-05-24 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US20070276345A1 (en) * | 2006-05-26 | 2007-11-29 | Raymond Huey | Clay-based hemostatic agents and devices for the delivery thereof |
US8114433B2 (en) * | 2006-05-26 | 2012-02-14 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US20080027365A1 (en) * | 2006-06-01 | 2008-01-31 | Huey Raymond J | Hemostatic device with oxidized cellulose pad |
US20080085300A1 (en) * | 2006-10-06 | 2008-04-10 | Z-Medica Corporation | Hemostatic compositions and method of manufacture |
US20080097271A1 (en) * | 2006-10-20 | 2008-04-24 | Z-Medica Corporation | Devices and methods for the delivery of hemostatic agents to bleeding wounds |
US20080125686A1 (en) * | 2006-11-29 | 2008-05-29 | Denny Lo | Heat mitigating hemostatic agent |
US20090043268A1 (en) * | 2007-08-06 | 2009-02-12 | Eddy Patrick E | Wound treatment system and suction regulator for use therewith |
US20090047366A1 (en) * | 2007-08-15 | 2009-02-19 | Bedard Robert L | Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants |
US20090053288A1 (en) * | 2007-08-20 | 2009-02-26 | Eskridge Jr E Stan | Hemostatic woven fabric |
US20090112170A1 (en) * | 2007-10-26 | 2009-04-30 | Electrochemical Oxygen Concepts, Inc | Apparatus and methods for controlling tissue oxygenation for wound healing and promoting tissue viability |
US20090123525A1 (en) * | 2007-11-09 | 2009-05-14 | Bedard Robert L | Adsorbent-Containing Hemostatic Devices |
US20110064785A1 (en) * | 2007-12-06 | 2011-03-17 | Nanosys, Inc. | Nanostructure-Enhanced Platelet Binding and Hemostatic Structures |
US20100035045A1 (en) * | 2008-01-21 | 2010-02-11 | Imerys Pigments, Inc. | Fibers comprising at least one filler and processes for their production |
US20110059287A1 (en) * | 2008-01-21 | 2011-03-10 | Imerys Pigments, Inc. | Fibers comprising at least one filler, processes for their production, and uses thereof |
US20110015565A1 (en) * | 2009-07-15 | 2011-01-20 | Hursey Francis X | Gas dispenser with therapeutic agent |
US20120004636A1 (en) * | 2010-07-02 | 2012-01-05 | Denny Lo | Hemostatic fibrous material |
US20120070470A1 (en) * | 2010-09-22 | 2012-03-22 | Z-Medica Corporation | Hemostatic compositions, devices, and methods |
Non-Patent Citations (1)
Title |
---|
Webster's Dictionary definition of "expose" (1993) * |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8475658B2 (en) | 2003-01-29 | 2013-07-02 | Molycorp Minerals, Llc | Water purification device for arsenic removal |
US8252344B2 (en) | 2003-09-12 | 2012-08-28 | Z-Medica Corporation | Partially hydrated hemostatic agent |
US8257731B2 (en) | 2005-02-09 | 2012-09-04 | Z-Medica Corporation | Devices and methods for the delivery of molecular sieve materials for the formation of blood clots |
US8557278B2 (en) | 2005-02-09 | 2013-10-15 | Z-Medica, Llc | Devices and methods for the delivery of blood clotting materials to bleeding wounds |
US8512743B2 (en) | 2005-02-09 | 2013-08-20 | Z-Medica, Llc | Devices and methods for the delivery of molecular sieve materials for the formation of blood clots |
US8938898B2 (en) | 2006-04-27 | 2015-01-27 | Z-Medica, Llc | Devices for the identification of medical products |
US8784876B2 (en) | 2006-05-26 | 2014-07-22 | Z-Medica, Llc | Clay-based hemostatic agents and devices for the delivery thereof |
US11123451B2 (en) | 2006-05-26 | 2021-09-21 | Z-Medica, Llc | Hemostatic devices |
US9867898B2 (en) | 2006-05-26 | 2018-01-16 | Z-Medica, Llc | Clay-based hemostatic agents |
US8343537B2 (en) | 2006-05-26 | 2013-01-01 | Z-Medica, Llc | Clay-based hemostatic agents and devices for the delivery thereof |
US9078782B2 (en) | 2006-05-26 | 2015-07-14 | Z-Medica, Llc | Hemostatic fibers and strands |
US8383148B2 (en) | 2006-05-26 | 2013-02-26 | Z-Medica, Llc | Clay-based hemostatic agents and devices for the delivery thereof |
US10960101B2 (en) | 2006-05-26 | 2021-03-30 | Z-Medica, Llc | Clay-based hemostatic agents |
US8460699B2 (en) | 2006-05-26 | 2013-06-11 | Z-Medica, Llc | Clay-based hemostatic agents and devices for the delivery thereof |
US8202532B2 (en) | 2006-05-26 | 2012-06-19 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US8257732B2 (en) | 2006-05-26 | 2012-09-04 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US10086106B2 (en) | 2006-05-26 | 2018-10-02 | Z-Medica, Llc | Clay-based hemostatic agents |
US8114433B2 (en) | 2006-05-26 | 2012-02-14 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US9333117B2 (en) | 2006-05-26 | 2016-05-10 | Z-Medica, Llc | Clay-based hemostatic agents and devices for the delivery thereof |
US8846076B2 (en) | 2006-05-26 | 2014-09-30 | Z-Medica, Llc | Hemostatic sponge |
US7968114B2 (en) | 2006-05-26 | 2011-06-28 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US8066874B2 (en) | 2006-12-28 | 2011-11-29 | Molycorp Minerals, Llc | Apparatus for treating a flow of an aqueous solution containing arsenic |
US8557730B2 (en) | 2007-10-31 | 2013-10-15 | Molycorp Minerals, Llc | Composition and process for making the composition |
US8349764B2 (en) | 2007-10-31 | 2013-01-08 | Molycorp Minerals, Llc | Composition for treating a fluid |
US8252087B2 (en) | 2007-10-31 | 2012-08-28 | Molycorp Minerals, Llc | Process and apparatus for treating a gas containing a contaminant |
US8858969B2 (en) | 2010-09-22 | 2014-10-14 | Z-Medica, Llc | Hemostatic compositions, devices, and methods |
US11007218B2 (en) | 2010-09-22 | 2021-05-18 | Z-Medica, Llc | Hemostatic compositions, devices, and methods |
US9889154B2 (en) | 2010-09-22 | 2018-02-13 | Z-Medica, Llc | Hemostatic compositions, devices, and methods |
US9233863B2 (en) | 2011-04-13 | 2016-01-12 | Molycorp Minerals, Llc | Rare earth removal of hydrated and hydroxyl species |
WO2013040080A1 (en) * | 2011-09-12 | 2013-03-21 | Protege Biomedical, Llc | Composition and dressing for wound treatment |
US9408913B2 (en) | 2011-09-12 | 2016-08-09 | Protege Biomedical, Llc | Composition and dressing for wound treatment |
CN102366640A (en) * | 2011-10-14 | 2012-03-07 | 浙江安吉华埠实业有限公司 | Zeolite tourniquet bandage |
US11559601B2 (en) | 2012-06-22 | 2023-01-24 | Teleflex Life Sciences Limited | Hemostatic devices |
US9072806B2 (en) | 2012-06-22 | 2015-07-07 | Z-Medica, Llc | Hemostatic devices |
US9603964B2 (en) | 2012-06-22 | 2017-03-28 | Z-Medica, Llc | Hemostatic devices |
US9352066B2 (en) | 2012-06-22 | 2016-05-31 | Z-Medica, Llc | Hemostatic devices |
US10960100B2 (en) | 2012-06-22 | 2021-03-30 | Z-Medica, Llc | Hemostatic devices |
US10577259B2 (en) | 2014-03-07 | 2020-03-03 | Secure Natural Resources Llc | Removal of arsenic from aqueous streams with cerium (IV) oxide compositions |
US9975787B2 (en) | 2014-03-07 | 2018-05-22 | Secure Natural Resources Llc | Removal of arsenic from aqueous streams with cerium (IV) oxide compositions |
US10959655B2 (en) | 2014-06-13 | 2021-03-30 | Kurin, Inc. | Catheter insertion device with blood analyzer |
US11832944B2 (en) | 2015-07-24 | 2023-12-05 | Kurin, Inc. | Blood sample optimization device |
US11963769B2 (en) | 2015-07-24 | 2024-04-23 | Kurin, Inc. | Blood sample optimization system and blood contaminant sequestration device and method |
US11744494B2 (en) | 2017-02-10 | 2023-09-05 | Kurin, Inc. | Blood contaminant sequestration device with one-way air valve and air-permeable blood barrier with closure mechanism |
Also Published As
Publication number | Publication date |
---|---|
US8252344B2 (en) | 2012-08-28 |
EP1667623B1 (en) | 2010-11-24 |
EP1667623A2 (en) | 2006-06-14 |
US20050058721A1 (en) | 2005-03-17 |
WO2005027834A2 (en) | 2005-03-31 |
ATE489062T1 (en) | 2010-12-15 |
EP1667623A4 (en) | 2008-02-27 |
WO2005027834A3 (en) | 2005-09-09 |
DE602004030264D1 (en) | 2011-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090299253A1 (en) | Blood clotting compositions and wound dressings | |
US7595429B2 (en) | Calcium zeolite hemostatic agent | |
EP1679087B1 (en) | Molecular sieve materials having increased particle size for the formation of blood clots | |
US8557278B2 (en) | Devices and methods for the delivery of blood clotting materials to bleeding wounds | |
US20080145455A1 (en) | Combination of Inorganic Hemostatic Agents with Other Hemostatic Agents | |
TW200906421A (en) | Method of providing hemostasis in anti-coagulated blood | |
US20080254147A1 (en) | Method of providing hemostasis in anti-coagulated blood | |
US20080125686A1 (en) | Heat mitigating hemostatic agent | |
US20090047366A1 (en) | Inorganic Coagulation Accelerators for Individuals taking Platelet Blockers or Anticoagulants | |
US20080063697A1 (en) | Use of Unactivated Calcium Exchanged Zeolites in Hemostatic Devices and Products | |
US20080145447A1 (en) | Inorganic Solids That Accelerate Coagulation of Blood | |
MX2007004802A (en) | Molecular sieve materials having increased particle size for the formation of blood clots | |
EP2059187A2 (en) | Use of noncalcium zeolites with added calcium salt in hemostatic devices and products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: Z-MEDICA, LLC, CONNECTICUT Free format text: MERGER;ASSIGNOR:Z-MEDICA CORPORATION;REEL/FRAME:028896/0108 Effective date: 20120831 |
|
AS | Assignment |
Owner name: ABACUS FINANCE GROUP, LLC, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:Z-MEDICA, LLC;REEL/FRAME:028917/0898 Effective date: 20120905 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: Z-MEDICA, LLC, CONNECTICUT Free format text: RELEASE AND REASSIGNMENT;ASSIGNOR:ABACUS FINANCE GROUP, LLC;REEL/FRAME:035389/0800 Effective date: 20150401 |
|
AS | Assignment |
Owner name: TELEFLEX LIFE SCIENCES LIMITED, MALTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:Z-MEDICA, LLC;REEL/FRAME:058740/0387 Effective date: 20211210 |
|
AS | Assignment |
Owner name: TELEFLEX LIFE SCIENCES II LLC, DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TELEFLEX LIFE SCIENCES LIMITED;REEL/FRAME:066434/0248 Effective date: 20231211 |
|
AS | Assignment |
Owner name: TELEFLEX LIFE SCIENCES II LLC, DELAWARE Free format text: CHANGE OF NAME;ASSIGNOR:TELEFLEX TECHNOLOGIES LLC;REEL/FRAME:066836/0737 Effective date: 20231219 Owner name: TELEFLEX TECHNOLOGIES LLC, DELAWARE Free format text: MERGER;ASSIGNOR:TELEFLEX LIFE SCIENCES II LLC;REEL/FRAME:066707/0695 Effective date: 20231218 |